Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lukas Biomedical's share price for the quarter that ended in Dec. 2025 was NT$31. Lukas Biomedical's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 41.9 Mil. Therefore, Lukas Biomedical's market cap for the quarter that ended in Dec. 2025 was NT$1,298.1 Mil.
Lukas Biomedical's quarterly market cap
declined
from Dec. 2024 (NT$1,249.9 Mil) to Jun. 2025 (NT$883.5 Mil) but then
increased
from Jun. 2025 (NT$883.5 Mil) to Dec. 2025 (NT$1,298.1 Mil).
Lukas Biomedical's annual market cap
increased
from Dec. 2023 (NT$1,115.4 Mil) to Dec. 2024 (NT$1,249.9 Mil) and
increased
from Dec. 2024 (NT$1,249.9 Mil) to Dec. 2025 (NT$1,298.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lukas Biomedical's Enterprise Value for Today is NT$1,153.5 Mil.
Lukas Biomedical (ROCO:6814) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lukas Biomedical Market Cap Related Terms
Lukas Biomedical Market Cap Historical Data
* Premium members only.
The historical data trend for Lukas Biomedical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6814 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Lukas Biomedical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lukas Biomedical Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Market Cap distribution charts can be found below:
* The bar in red indicates where Lukas Biomedical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lukas Biomedical's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lukas Biomedical (ROCO:6814) has a Market Cap of NT$1,032.2 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lukas Biomedical and its competitors. According to the industry distribution chart, Lukas Biomedical ranks #1007 out of 1423 companies in the Biotechnology industry, placing it in the top 70.8%.
Is Lukas Biomedical's Market Cap too high?
Lukas Biomedical's current Market Cap is NT$1,032.2 Mil. Based on the distribution chart, Lukas Biomedical ranks #1007 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #1007 out of 1423 companies for Market Cap. This places Lukas Biomedical in the lower half of its industry. The industry median Market Cap is 113.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.11, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median Market Cap is 113.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current Market Cap is NT$1,032.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.65 — trading 13.2% above its estimated fair value. The current Market Cap is NT$1,032.2 Mil. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Market Cap is NT$1,032.2 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?
Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued.
The current stock price of NT$24.65 is trading 13.2% above its estimated GF Value™ of NT$21.77.
GuruFocus considers Lukas Biomedical to be Modestly Overvalued.
Key valuation signals for ROCO:6814:
Market Cap: NT$1,032.2 Mil
GF Value™: NT$21.77 vs. price of NT$24.65 (13.2% above fair value)
No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score
Get the complete analysis for ROCO:6814
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6814 has been successfully added to your 
